Covered recipient · General Payments record
ENRIQUE FEOLI
Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology
General Payments · PY2018–2024
$5,554.92
- Reported across 339 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $459.13 | 14 |
| Education | $16.72 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| NEUROPACE, INC. | $161.52 | 1 |
| UCB, Inc. | $75.41 | 4 |
| SK Life Science, Inc. | $61.81 | 4 |
| Pyros Pharmaceuticals, Inc. | $58.26 | 1 |
| BIOCODEX, INC. | $50.61 | 1 |
| CATALYST PHARMACEUTICALS, INC. | $40.34 | 2 |
| Aucta Pharmaceuticals, Inc. | $27.90 | 2 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (15)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Aucta Pharmaceuticals, Inc. | $13.67 | 03/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147904882 | CMS |
| Aucta Pharmaceuticals, Inc. | $14.23 | 06/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147905622 | CMS |
| BIOCODEX, INC. | $50.61 | 02/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146420210 | CMS |
| CATALYST PHARMACEUTICALS, INC. | $23.62 | 04/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1144446874 | CMS |
| CATALYST PHARMACEUTICALS, INC. | $16.72 | 09/11/2024 | Education | Undisputed | 01/23/2026 | 1144446876 | CMS |
| NEUROPACE, INC. | $161.52 | 04/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153272560 | CMS |
| Pyros Pharmaceuticals, Inc. | $58.26 | 07/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145043260 | CMS |
| SK Life Science, Inc. | $15.18 | 03/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1154115359 | CMS |
| SK Life Science, Inc. | $16.87 | 04/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1154115373 | CMS |
| SK Life Science, Inc. | $14.55 | 05/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1154115385 | CMS |
| SK Life Science, Inc. | $15.21 | 06/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1154115393 | CMS |
| UCB, Inc. | $19.55 | 04/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143109390 | CMS |
| UCB, Inc. | $16.36 | 05/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143109392 | CMS |
| UCB, Inc. | $18.26 | 05/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143109394 | CMS |
| UCB, Inc. | $21.24 | 07/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143109396 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.